Gudrun Piringer Jörn Decker Vera Trommet Thomas Kühr Sonja Heibl Konrad Dörfler Josef Thaler
10.3389/fonc.2023.1166545
Front Oncol
2023 May 5;13:1166545.
braf-v600 mutation mss combination targeted therapy dabrafenib trametinib
CC BY
https://pubmed.ncbi.nlm.nih.gov/37213293/
Case Reports
PMC10196488
37213293
Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
2023